WO2002074304A3 - Zusammensetzung, enthaltend einen gallium(iii)-komplex und ein therapeutisch wirksames zytostatikum - Google Patents

Zusammensetzung, enthaltend einen gallium(iii)-komplex und ein therapeutisch wirksames zytostatikum Download PDF

Info

Publication number
WO2002074304A3
WO2002074304A3 PCT/EP2002/003029 EP0203029W WO02074304A3 WO 2002074304 A3 WO2002074304 A3 WO 2002074304A3 EP 0203029 W EP0203029 W EP 0203029W WO 02074304 A3 WO02074304 A3 WO 02074304A3
Authority
WO
WIPO (PCT)
Prior art keywords
gallium
iii
complex
therapeutically effective
composition containing
Prior art date
Application number
PCT/EP2002/003029
Other languages
English (en)
French (fr)
Other versions
WO2002074304A2 (de
Inventor
Bernhard Keppler
Original Assignee
Faustus Forschungs Cie
Bernhard Keppler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faustus Forschungs Cie, Bernhard Keppler filed Critical Faustus Forschungs Cie
Publication of WO2002074304A2 publication Critical patent/WO2002074304A2/de
Publication of WO2002074304A3 publication Critical patent/WO2002074304A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Zusammensetzung, enthaltend einen Gallium(III)-Komplex und ein therapeutisch wirksames Zytostatikum, wie Cisplatin, carboplatin oder Oxaliplatin, und deren Verwendung zur Prophylaxe und/oder Behandlung von Krebserkrankungen.
PCT/EP2002/003029 2001-03-19 2002-03-19 Zusammensetzung, enthaltend einen gallium(iii)-komplex und ein therapeutisch wirksames zytostatikum WO2002074304A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10113185.2 2001-03-19
DE10113185A DE10113185A1 (de) 2001-03-19 2001-03-19 Zusammensetzung, enthaltend einen Gallium(III)-Komplex und einen therapeutisch wirksamen Platin-Komplex

Publications (2)

Publication Number Publication Date
WO2002074304A2 WO2002074304A2 (de) 2002-09-26
WO2002074304A3 true WO2002074304A3 (de) 2003-01-09

Family

ID=7678023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/003029 WO2002074304A2 (de) 2001-03-19 2002-03-19 Zusammensetzung, enthaltend einen gallium(iii)-komplex und ein therapeutisch wirksames zytostatikum

Country Status (2)

Country Link
DE (1) DE10113185A1 (de)
WO (1) WO2002074304A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT501262B8 (de) * 2005-01-24 2007-02-15 Faustus Forschung Translationa Verwendung von gallium(iii)-komplexen zur behandlung von tumoren des urothelialtraktes
AT501819B1 (de) * 2005-04-18 2007-01-15 Faustus Forschung Translationa Verwendung von gallium(iii)-komplexen zur behandlung von tumorerkrankungen der leber
AT503317B1 (de) * 2006-02-13 2007-09-15 Faustus Forschung Translationa Verwendung von gallium(iii)-komplexen zur herstellung eines medikaments zur behandlung von melanomen
EP2413698A4 (de) 2009-03-30 2013-07-10 Niiki Pharma Inc Verfahren zur behandlung von osteoporose
CA2831206A1 (en) * 2010-04-23 2011-10-27 Niiki Pharma Inc. Method for treating pancreatic cancer
WO2012075211A2 (en) * 2010-12-01 2012-06-07 Niiki Pharma Inc. Combination therapy with a gallium complex

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002087A1 (en) * 1991-07-25 1993-02-04 Les Laboratoires Meram Gallium (iii) complexes, process for their obtention and pharmaceutical compositions containing them
WO1993009776A1 (en) * 1991-11-12 1993-05-27 Lawrence Richard Bernstein Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
EP0964459A2 (de) * 1998-06-09 1999-12-15 Bayer Aktiengesellschaft Elektrolumineszierende Anordnungen mit N-Alkyl-2,2'-imino-bis-(8-hydroxychinolin)-Metallkomplexen
US6087354A (en) * 1989-11-22 2000-07-11 Bernstein; Lawrence Richard Gallium complexes of 3-hydroxy-4-pyrones to treat cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012193A1 (fr) * 1992-11-24 1994-06-09 Debiopharm S.A. Combinaison de cisplatine avec l'oxaliplatine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087354A (en) * 1989-11-22 2000-07-11 Bernstein; Lawrence Richard Gallium complexes of 3-hydroxy-4-pyrones to treat cancer
WO1993002087A1 (en) * 1991-07-25 1993-02-04 Les Laboratoires Meram Gallium (iii) complexes, process for their obtention and pharmaceutical compositions containing them
WO1993009776A1 (en) * 1991-11-12 1993-05-27 Lawrence Richard Bernstein Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
EP0964459A2 (de) * 1998-06-09 1999-12-15 Bayer Aktiengesellschaft Elektrolumineszierende Anordnungen mit N-Alkyl-2,2'-imino-bis-(8-hydroxychinolin)-Metallkomplexen

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANTICANCER RESEARCH, vol. 14, no. 6A, 1994, pages 2299 - 2306, ISSN: 0250-7005 *
CANCER LETTERS, vol. 129, no. 2, 17 July 1998 (1998-07-17), pages 199 - 204, XP002205844, ISSN: 0304-3835 *
CANCER RESEARCH, vol. 50, no. 20, 1990, pages 6466 - 6470, ISSN: 0008-5472 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 17 July 1998 (1998-07-17), MYETTE MICHAEL S ET AL: "Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: Effects on the proliferation of human leukemic cells.", XP002205846, Database accession no. PREV199800408817 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1990, LUNDBERG J H ET AL: "INTERACTION OF GALLIUM NITRATE WITH FLUDARABINE AND IRON CHELATORS EFFECTS ON THE PROLIFERATION OF HUMAN LEUKEMIC HL60 CELLS", XP002205847, Database accession no. PREV199191006806 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, COLLERY P ET AL: "Dose Optimization of Gallium Chloride, Orally Administered, in Combination with Platinum Compounds.", XP002205848, Database accession no. PREV199598143266 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2001 (2001-03-01), JAKUPEC MICHAEL A ET AL: "Interactions of tris(8-quinolinolato)gallium(III) (KP46) with platinum drugs in ovarian and colon carcinoma cells.", XP002205845, Database accession no. PREV200100448802 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; COLLERY, P. ET AL: "New gallium complexes for a cisplatin combination therapy", XP002205849, retrieved from STN Database accession no. 120:94942 *
MET. IONS BIOL. MED., PROC. INT. SYMP., 2ND (1992), 173-5. EDITOR(S): ANASTASSOPOULOU, JANE. PUBLISHER: LIBBEY, MONTROUGE, FR., XP001084414 *
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL HTTP://AACR01.AGORA.COM/PLANNER/DISPLAYABSTRACT.ASP?PRESENTATIONID=17718; ONLINE PUBLICATION DATE: FEBRUARY 17, 2001, vol. 42, 92nd Annual Meeting of the American Association for Cancer Research;New Orleans, LA, USA; March 24-28, 2001, pages 425, XP002205843, ISSN: 0197-016X *

Also Published As

Publication number Publication date
WO2002074304A2 (de) 2002-09-26
DE10113185A1 (de) 2002-10-24

Similar Documents

Publication Publication Date Title
WO2003049702A3 (en) Vanilloid receptor ligands and their use in treatments
DE602004021472D1 (en) Pyrimiidinverbindungen
SE0102315D0 (sv) Compounds
WO2002080890A3 (en) A jasmonate pharmaceutical composition for treatment of cancer
WO2006073457A8 (en) Bioactive compounds and methods of uses thereof
WO2005013996A3 (en) 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
WO2002048147A3 (en) Pyrazolopyridines
AP2000001942A0 (en) Use of organophosphoric compounds for the therapeutic and preventative treatment of infections.
WO2003095455A3 (en) Substituted pyrazolopyrimidines
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
WO2007106192A3 (en) Inhibitors of iap
DE60112330D1 (en) Pyrazolopyridinderivate
WO2002102793A3 (en) Quinazolinediones as antibacterial agents
MXPA03011906A (es) Derivados de imidazo' 1,2-a-piridina para la profilaxis y el tratamiento de infecciones virales por herpes.
TW200603783A (en) Non-nucleoside reverse transcriptase inhibitors
MXPA04003796A (es) Tioacetamidas sustituidas.
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
WO2006023843A3 (en) Novel heterocycles
MXPA04000185A (es) Nuevos derivados de oxazolidinonas como agentes antibacterianos.
HK1093729A1 (en) Substituted quinolones
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
TW200621260A (en) Selected fused heterocyclics and uses thereof
WO2003101382A3 (en) Compounds useful in the treatment of anthrax and inhibiting lethal factor
WO2002074304A3 (de) Zusammensetzung, enthaltend einen gallium(iii)-komplex und ein therapeutisch wirksames zytostatikum

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP